Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

Despite the availability of vaccines, there remains an urgent need for antiviral drugs with potent activity against SARS-CoV-2, the cause of COVID-19. Millions of people are immune-suppressed and may not be able to mount a fully protective immune response after vaccination. There is also an increasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Painter, George R, Natchus, Michael G, Cohen, Oren, Holman, Wendy, Painter, Wendy P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277160/
https://www.ncbi.nlm.nih.gov/pubmed/34271264
http://dx.doi.org/10.1016/j.coviro.2021.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277160/
https://www.ncbi.nlm.nih.gov/pubmed/34271264
http://dx.doi.org/10.1016/j.coviro.2021.06.003

Ejemplares similares